Clinical & Translational Immunology (Jan 2022)

Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia

  • Gabrielle M Haeusler,
  • Alexandra L Garnham,
  • Connie SN Li‐Wai‐Suen,
  • Julia E Clark,
  • Franz E Babl,
  • Zoe Allaway,
  • Monica A Slavin,
  • Francoise Mechinaud,
  • Gordon K Smyth,
  • Bob Phillips,
  • Karin A Thursky,
  • Marc Pellegrini,
  • Marcel Doerflinger

DOI
https://doi.org/10.1002/cti2.1383
Journal volume & issue
Vol. 11, no. 5
pp. n/a – n/a

Abstract

Read online

Abstract Objectives Febrile neutropenia (FN) is a major cause of treatment disruption and unplanned hospitalization in childhood cancer patients. This study investigated the transcriptome of peripheral blood mononuclear cells (PBMCs) in children with cancer and FN to identify potential predictors of serious infection. Methods Whole‐genome transcriptional profiling was conducted on PBMCs collected during episodes of FN in children with cancer at presentation to the hospital (Day 1; n = 73) and within 8–24 h (Day 2; n = 28) after admission. Differentially expressed genes as well as gene pathways that correlated with clinical outcomes were defined for different infectious outcomes. Results Global differences in gene expression associated with specific immune responses in children with FN and documented infection, compared to episodes without documented infection, were identified at admission. These differences resolved over the subsequent 8–24 h. Distinct gene signatures specific for bacteraemia were identified both at admission and on Day 2. Differences in gene signatures between episodes with bacteraemia and episodes with bacterial infection, viral infection and clinically defined infection were also observed. Only subtle differences in gene expression profiles between non‐bloodstream bacterial and viral infections were identified. Conclusion Blood transcriptome immune profiling analysis during FN episodes may inform monitoring and aid in defining adequate treatment for different infectious aetiologies in children with cancer.

Keywords